Orion’s collaboration partner Bayer announced the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the oral androgen...
SPEXIS AG, a clinical-stage biopharmaceutical company, announced that its CXCR4 inhibitor balixafortide demonstrated synergistic efficacy in combination with docetaxel compared to either drug alone...
